News

This page will document some recent news article and research findings on rcc.

26 June 2011BMA: ‘Let patients die to save cash’
Scotland on Sunday front page story – the head of BMA Scotland questions spending NHS money on life extending cancer drugs.
Scotland on Sunday

07 March 2011
The Scottish Medical Council approves the use of Votrient (pazopanib) for stage IV kidney cancer patients in Scotland (it had previously been approved by NICE for patients in England and Wales.
Pharmiweb

10 Sept 2010
A medical abstract of a study which indicated a long term response (28 months) to evorilimus (‘Afinitor’) in a 70 year old man with metastatic rcc with progressive liver metastases. This abstract does indicate that evorilimus was used in the “approved manner”- i.e., after a course of Sutent.

Long term response with evorilimus for metatastic rcc 100910

09 Sept 2010 ‘Healthful’ Antioxidants  that can aggravate kidney cancer
Care2.com

08 Sept 2010 Medical abstract. Influence of visceral obesity on oncologic outcome in patients with renal cell carcinoma. NB: Visceral adipose tissue (VAT) means  body fat. This abstract includes the following info:
“Patients with high VAT had significantly higher cumulative cause-specific survival when compared to patients with low VAT (p = 0.0257). VAT was associated with better clinical features in patients with RCC”
So, I am liberally interpreting it as backing up my theory that being fat will help me to fight cancer!
Influence of visceral obesity on oncologic outcome in patients with renal cell carcinoma 091010

05 Sept 2010 ‘When oncology becomes hope-ology’ – Malaysian oncologist muses on the fact that stage iv rcc patients always assume they will be in the 5-10 percentile who will survive for more than 5 years.
The Star (Malaysia)

25 Aug 2010
Summary of advances in treating metastatic kidney cancer
EmpowHer

24 Aug 2010 After a course of Avastin (not available on the NHS!) Jill de Cruz’s advanced kidney cancer is in remission
The Daily Mail

Leave a Reply

Your email address will not be published. Required fields are marked *

*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>